PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Paclitaxel
Related studies linked through entity extraction aliases.
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
- Status
- UNKNOWN
- Phase
- PHASE1
Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
- Status
- UNKNOWN
- Phase
- NA
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
- Status
- COMPLETED
- Phase
- PHASE3
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
- Status
- COMPLETED
- Phase
- PHASE3
Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE3
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1